The Lead
This cluster spans the core methodological literature in clinical trial statistics and biostatistics, covering adaptive designs, Bayesian frameworks, covariate adjustment, causal inference, survival analysis, win ratio methods, dose-finding, estimands, and real-world evidence. The editorial thread is the active frontier of statistical methodology shaping how trials are designed, analyzed, and regulated—from phase I dose escalation to confirmatory RCTs and post-market evidence generation.
Five years after ICH E9(R1) was finalized, the average Phase III SAP still can’t demonstrate that its censoring rules are coherent with its declared intercurrent-event strategy—and a regulator may notice before the sponsor does. This cycle’s literature maps the unfinished work in oncology crossover adjustment, Bayesian borrowing methods that regulators haven’t formally qualified for pivotal use, a covariate adjustment field that spent decades leaving efficiency on the table, and causal estimators that can point in the wrong direction when applied to competing events—none of which is abstract, and all of which has a submission decision attached to it.
Read the full lead →
Two methodological problems — what to do when your control arm becomes unethical mid-enrollment, and whether Duration of Response measures anything it purports to — are now explicitly on FDA’s pre-guidance radar, with trial restart and a multi-state DoR replacement both on the table.
Read more →
If you’ve ever improvised a validation cohort justification in front of an FDA reviewer asking about pre-specified F1 thresholds, the psF1 framework — confidence intervals, hypothesis tests, prospective power calculations, open-source R package, citable — is the infrastructure you were missing. The other three papers are worth knowing; this one has the shortest path to your SAP appendix.
Read more →
FDA apparently pre-approved Moderna’s comparator, then rejected the filing anyway — and every other jurisdiction accepted it. For biometrics teams, the operational consequence is blunt: End-of-Phase 2 and pre-BLA meeting agreements may no longer anchor agency expectations, and the partial reversal swapped one design problem for several worse ones.
Read more →
Three new papers quietly audit choices the industry has been making on autopilot — the statistical method embedded in your QTL alerting engine, the sample-size assumptions behind your specification limits, and whether normal-based intervals are quietly inflating bounds on your bounded CMC data.
Read more →
-
New SBR Paper Claims Standard Meta-Analytic Estimators Are Structurally Inconsistent.
A peer-reviewed paper in Statistics in Biopharmaceutical Research argues that mainstream meta-analytic methods applied to clinical trials produce strongly inconsistent estimators — meaning structural bias that more trials or more patients cannot fix. The claim, if it holds under scrutiny, cuts directly at the evidentiary foundations of regulatory pooled analyses, HTA dossiers, and systematic reviews. The precise mechanism (heterogeneity misspecification, aggregate vs. IPD data, exchangeability violations, or some combination) requires reading the full paper; sweeping indictments of this kind sometimes hinge on specific model configurations that don’t generalize universally.
-
Three New Papers Advance Stepwise MTPs for Co-Primary Endpoint Trials.
Recent issues of Journal of Biopharmaceutical Statistics and Statistics in Biopharmaceutical Research add methodological depth to multiplicity strategy for co-primary endpoints: a Holm-related MTP targeting rejection of at least k-of-n hypotheses (with proven strong FWER control and simultaneous confidence regions), a stepwise family interpolating between Holm and the max-p-value MTP for settings requiring all or some co-primaries significant, and improved trimmed weighted Hochberg procedures for the two-endpoint case paired with sample size optimization. All three are directly relevant to SAP and protocol development, though regulatory acceptance of trimming assumptions and k-of-n rejection frameworks will require explicit alignment with FDA/EMA multiplicity guidance.
-
Systematic Review Questions Whether Multiple Imputation Materially Outperforms Complete Case Analysis.
A systematic review in Clinical Trials (SAGE) takes an empirical look at whether multiple imputation actually moves the needle on treatment effect estimates compared to complete case analysis across published trials — a pointed question for biostatisticians drafting SAPs and justifying missing data strategies under ICH E9(R1). The abstract is truncated and full conclusions remain unconfirmed ahead of print, so actionable takeaways require the full paper; if MI is shown to rarely alter inferential outcomes, expect pressure on the reflexive inclusion of MI as standard SAP boilerplate and sensitivity analysis hierarchies.
-
MHRA AI Airlock Publishes Pilot Reports, Advances to Phase 2.
The MHRA’s AI Airlock sandbox published four pilot-phase reports in October 2025 covering explainability, hallucination evaluation, and post-market surveillance/continuous monitoring for AIaMD — all non-binding, but flagged as direct inputs to MHRA’s National Commission into the Regulation of AI in Healthcare. Phase 2 is now underway with seven technologies (including cancer diagnostics and clinical note-taking AI) targeting adaptive AI management and PMS frameworks, with reports expected Summer 2026; multi-year funding secured in April 2026 signals this sandbox is a durable fixture, not a pilot experiment. For biostatisticians and algorithmic validation leads, the hallucination evaluation and continuous monitoring outputs are the ones to read first.
-
On-Treatment Analyses Carry Hidden Bias When Dosing Schedules Differ.
A new paper in Statistics in Biopharmaceutical Research identifies systematic bias in on-treatment analyses when trial arms differ in dosing frequency — think daily oral vs. monthly injectable — where asymmetric exposure windows and differential censoring structures distort comparative estimates. The finding is directly relevant to ICH E9(R1) estimand construction: “while on treatment” intercurrent event strategies require careful alignment with dosing interval differences, or they risk embedding bias into the primary analysis. Biostatisticians writing SAPs for any trial with mismatched dosing schedules should scrutinize on-treatment definitions and censoring rules before locking.
-
Cross-Sectional Audit Benchmarks Trial Design Quality Behind 2020–2023 EMA Approvals.
A new cross-sectional study in Clinical Trials (SAGE) characterizes the evidentiary basis of EMA drug approvals from 2020–2023, cataloguing design features including randomization, blinding, control type, endpoint selection, and results transparency — capturing a window that spans pandemic-era rolling reviews, conditional marketing authorizations, and accelerated assessments. For biostatisticians and trial designers, the practical value is in the benchmarking: what design concessions regulators actually accepted, which informs defensible choices on surrogate endpoints, single pivotal trial strategies, and open-label methodology in EMA submissions. The parallel with prior FDA-focused evidence audits also opens the door to cross-jurisdictional comparison of evidentiary thresholds.